-1200x645-800x430.jpg)
- TruScreen Ultra receives product registration from Ministry of Health Pharmacy and Poisons Board
- Cervical cancer leading cause of cancer death among Kenyan women
- Only 6.0% of Kenyan women aged 30 to 49 have been screened
- Kenya a market of more than 17 million women of screening age
TruScreen Group (ASX: TRU) has received product registration in the Republic of Kenya, a priority market for cervical cancer screening.
.png)
The company’s TruScreen Ultra product provides a real-time instant result at point of care, without the need for laboratory or specialist pathology infrastructure, supporting screening in rural and community health clinics.
Kenya has a population of 57.5 million, with 17 million women of screening age. It is East Africa’s largest economy and a regional hub for quality health care and NGO-funded public health programs.
Cervical cancer is the leading cause of cancer-related death among Kenyan women. The Ministry of Health reports approximately 6,000 new cases and 4,000 deaths each year. the equivalent of around 10 women dying every day from a preventable disease.
Screening coverage is very low. Kenya’s National Cervical Cancer Elimination Action Plan (NCCEAP) 2025–2030 sets a 2025 baseline of just 6% of women aged 30–49 screened with a high-performance test.2 The Plan commits Kenya to the WHO 90-70-90 targets by 2030: 90% HPV vaccination, 70% screening coverage and 90% treatment of precancer and invasive cancer.2
Increasing screening coverage from 6% to 70% by 2030 will require screening at scale, at the point of care nationally.
As a former British territory, independent since 1963 and a member of the Commonwealth, Kenya has English as an official language alongside Kiswahili. English is the language of government, regulation, medical training and clinical practice.
This heritage shortens TruScreen’s path to market. Clinical, training and regulatory materials can be used without translation, and Kenya’s health system shares common foundations with TruScreen’s established English-speaking markets.
Ansell Pharmaceuticalsis TruScreen’s distributor for Kenya, Somalia and South Sudan. Ansell is an experienced supplier of pharmaceuticals and medical devices for NGO-funded public health programs in East Africa. Ansell also facilitated programs for WHO and the UN.
Product training for the Ansell team will commence shortly, with product launch for public and private healthcare providers and engagement with key opinion leaders (KOL’s) planned for early 2027.
Kenya is the latest step in TruScreen’s African strategy, which targets public screening programs in eight nations – Zimbabwe, South Africa, Eswatini, Rwanda, Nigeria, Ghana, Côte d’Ivoire and Kenya – a screening market of up to 132 million women of screening age.
TRU was steady at 0.7¢ with a Mkt cap of $7.047M prior to markets opening.
Join the discussion: See what HotCopper users are saying about TruScreen Group and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.